Synairgen plc SNG

LON: SNG | ISIN: GB00B0381Z20   8/04/2025
0,950 GBX (+18,31%)
(+18,31%)   8/04/2025

5 april 2022 · Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference · Persbericht

6 januari 2022 · Synairgen announces global strategic partnership with Ashfield Engage · Persbericht

7 december 2021 · Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference · Persbericht

11 november 2021 · Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients · Persbericht

30 september 2021 · Non-Executive Director Appointment · Persbericht

30 september 2021 · Interim results for the six months ended 30 June 2021 · Persbericht

24 mei 2021 · Synairgen announces results of in vitro studies showing antiviral activity of interferon beta against key SARS-CoV-2 variants · Persbericht

12 mei 2021 · Preliminary results for the year ended 31 December 2020 · Persbericht

30 april 2021 · Synairgen announces data from Home Cohort of SG016 Phase II trial of inhaled interferon beta in COVID-19 patients and encouraging combined data for whole SG016 trial · Persbericht

15 februari 2021 · Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients · Persbericht

15 februari 2021 · Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients · Persbericht

25 januari 2021 · Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients · Persbericht

25 januari 2021 · Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients · Persbericht

20 januari 2021 · Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta · Persbericht

20 januari 2021 · Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta · Persbericht

13 januari 2021 · Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients · Persbericht

13 januari 2021 · Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients · Persbericht

Mijn selecties